Adolescent experiences of anti-obesity drugs

Clinical Obesity

Volumn 5, Issue 3, 2015, Pages 116-126

  White, B ^a   Jamieson, L ^b   Clifford, S ^c   Shield, J P H ^d   Christie, D ^e   Smith, F ^b   Wong, I C K ^f   Viner, R M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c ICON PLC   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adherence; Concordance; Metformin; Orlistat

Indexed keywords

ANTIOBESITY AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; LIFESTYLE; MALE; MEDICATION THERAPY MANAGEMENT; PERSONAL EXPERIENCE; PRESCRIPTION; PRIORITY JOURNAL; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 85047104047     PISSN: 17588103     EISSN: 17588111     Source Type: Journal    
DOI: 10.1111/cob.12101     Document Type: Article

References (14)

1. National Institute for Health and Care Excellence. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clinical Guideline 43. London 2006.
2. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32: 1743-1745.
3. Viner RM, Hsia Y, Tomsic T, Wong ICK. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev 2010; 11: 593-602.
4. Viner RM, Hsia Y, Neubert A, Wong IC. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. Br J Clin Pharmacol 2009; 68: 844-851.
5. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007; 31: 1567-1570.
6. McDuffie JR, Calis KA, Uwaifo GI etal. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642-650.
7. Today Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247-2256.
8. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995; 73: 25-29.
9. Guest G. How many interviews are enough?: An experiment with data saturation and variability. Field Methods 2006; 18: 59-82.
10. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3: 77-101.
11. Psarou A, Brown I. Patients' experiences of prescribed anti-obesity drugs and perceptions of support from primary care: a qualitative study. Prim Health Care Res Dev 2010; 11: 250-259.
12. Ogden J, Sidhu S. Adherence, behavior change, and visualization: a qualitative study of the experiences of taking an obesity medication. J Psychosom Res 2006; 61: 545-552.
13. Hollywood A, Ogden J. Taking orlistat: predicting weight loss over 6 months. J Obes 2011; 2011: 806896.
14. Hanghøj S, Boisen KA. Self-Reported Barriers to medication adherence among chronically Ill adolescents: a systematic review. J Adolesc Health 2014; 54: 121-138.